Frailty and cardiovascular safety of JAK inhibitors versus TNF inhibitors in rheumatoid arthritis: a real-world comparative study of drug effects and patient profiles
RA patients treated with JAKis in real-world settings have a risk of developing CVEs no higher than those of TNFi users, but potential signals remain for TEs, even if the sample was not sufficiently powered. Patient profiles, particularly the frailty, have a more substantial impact on the risk of CVEs than the specific disease-modifying anti-rheumatic drug (DMARD) choice.
Authors
- Alessandra Bortoluzzi (ORCID: https://orcid.org/0000-0003-2416-8134)
- Carlo Garaffoni
- Giuseppe Occhino (ORCID: https://orcid.org/0000-0002-7074-9354)
- Giuseppe Bellelli (ORCID: https://orcid.org/0000-0001-5430-0947)
- Paola Rebora (ORCID: https://orcid.org/0000-0003-0606-5852)
- Carlo Alberto Scirè (ORCID: https://orcid.org/0000-0001-7451-0271)
- Olivia Leoni (ORCID: https://orcid.org/0000-0002-6906-2424)
- Paolo Delvino (ORCID: https://orcid.org/0000-0002-6383-8236)
- Maria Grazia Valsecchi (ORCID: https://orcid.org/0000-0001-5574-3504)
- Ettore Silvagni (ORCID: https://orcid.org/0000-0001-7654-8222)
Institutions
- University of Ferrara (IT)
- Directorate of Health (IS)
- Azienda Ospedaliera San Gerardo (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-25
- DOI
- https://doi.org/10.3389/fphar.2025.1565909
- Citations
- 8
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 25.05
Funders
- Università degli Studi di Milano-Bicocca